Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Related Articles by Review for PubMed (Select 9007721)

1.

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R, Planas R, Jiménez W, Arroyo V, Rodés J.

J Hepatol. 1996 Dec;25(6):916-23.

PMID:
9007721
2.
3.

Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.

Schmidt LE, Ring-Larsen H.

Curr Pharm Des. 2006;12(35):4637-47. Review.

PMID:
17168767
4.

[Vasoconstrictors in the treatment of hepatorenal syndrome].

Ortega R, Calahorra B, Ginès P.

Nefrologia. 2002;22 Suppl 5:56-61. Review. Spanish. No abstract available.

PMID:
12107919
5.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
6.

[Update on hepatorenal syndrome].

Blaise P, Moonen M, Rorive G.

Nephrologie. 2002;23(1):11-7. Review. French.

PMID:
11887572
7.

The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.

Moreau R, Lebrec D.

Hepatology. 2006 Mar;43(3):385-94. Review.

PMID:
16496352
8.

Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage.

Döhler KD, Meyer M.

Best Pract Res Clin Anaesthesiol. 2008 Jun;22(2):335-50. Review.

PMID:
18683479
9.

Hepatorenal syndrome.

Gattoni A, Marotta F, Vangieri B, Pisani G, Cristiano F.

Clin Ter. 2004 Sep;155(9):375-89. Review.

PMID:
15700631
10.

Arachidonic acid derivatives and renal function in liver cirrhosis.

Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P.

Semin Nephrol. 1997 Nov;17(6):530-48. Review.

PMID:
9353864
11.
12.

Hepatorenal syndrome. New perspectives in pathogenesis and treatment.

Badalamenti S, Graziani G, Salerno F, Ponticelli C.

Arch Intern Med. 1993 Sep 13;153(17):1957-67. Review.

PMID:
8357280
13.

Hepatorenal syndrome.

Bataller R, Arroyo V, Ginès P, Sort P.

Forum (Genova). 1998 Jan-Mar;8(1):62-81. Review.

PMID:
9565447
14.

Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.

Karwa R, Woodis CB.

Ann Pharmacother. 2009 Apr;43(4):692-9. doi: 10.1345/aph.1L373. Epub 2009 Mar 18. Review.

PMID:
19299324
15.

Hepatorenal syndrome.

Guevara M, Ginès P.

Dig Dis. 2005;23(1):47-55. Review.

PMID:
15920325
16.

Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.

Meltzer J, Brentjens TE.

Curr Opin Anaesthesiol. 2010 Apr;23(2):139-44. doi: 10.1097/ACO.0b013e32833724a8. Review.

PMID:
20124895
17.

New clues to the pathophysiology of hepatorenal failure.

Lang F, Gerok W, Häussinger D.

Clin Investig. 1993 Feb;71(2):93-7. Review.

PMID:
8461632
18.

Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy.

Epstein M.

J Am Soc Nephrol. 1994 Apr;4(10):1735-53. Review.

19.

Is renal dose dopamine protective or therapeutic? Yes.

Carcoana OV, Hines RL.

Crit Care Clin. 1996 Jul;12(3):677-85. Review.

PMID:
8839599
20.

Renal functional impairment and sodium retention in liver cirrhosis.

Gentilini P, Laffi G.

Digestion. 1989;43(1-2):1-32. Review. No abstract available.

PMID:
2680695
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk